Blockchain Registration Transaction Record

ABVC BioPharma Secures $150K Milestone, Advances CNS Botanical Therapies

ABVC BioPharma announces a $150K licensing milestone, advancing CNS botanical therapies for MDD and ADHD, showcasing a 234% revenue increase and strategic global partnerships.

The development and commercialization of ABVC's botanical drug candidates for CNS disorders like MDD and ADHD represent a significant advancement in the search for alternative treatments. With a global shortage of such medications and the increasing prevalence of these conditions, ABVC's progress offers hope for millions of patients seeking effective and legal therapeutic options. The company's licensing-first strategy not only ensures a sustainable revenue stream but also minimizes shareholder dilution, making it a noteworthy development for investors and patients alike.